Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Protara Therapeutics ( (TARA) ) is now available.
Protara Therapeutics has announced the closing of a public offering of common stock and pre-funded warrants, raising approximately $100 million in gross proceeds. The funds are intended for the development of TARA-002 and other clinical programs, with potential additional use for working capital and corporate purposes, highlighting Protara’s commitment to advancing its therapeutic pipeline.
More about Protara Therapeutics
Protara Therapeutics, Inc. is a clinical-stage company focused on developing transformative therapies for cancer and rare diseases.
YTD Price Performance: 232.45%
Average Trading Volume: 2,138,584
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $128.9M
See more insights into TARA stock on TipRanks’ Stock Analysis page.
